Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nenad Sejic
Observed name:
N. Sejic
Institutions:
The University of Melbourne,
Walter and Eliza Hall Institute of Medical Research
Observed institutions:
The University of Melbourne,
Walter and Eliza Hall Institute of Medical Research,
University of Birmingham
OpenAlex ID:
A5044779055
First‐in‐human clinical trial of allogeneic, platelet‐derived extracellular vesicles as a potential therapeutic for delayed wound healing
2023
·
Jancy Johnson
, Sam Q. K. Law
, et al.
·
Journal of Extracellular Vesicles
·
203
PDF
EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins
2019
·
Leah Fitzsimmons
, Rachel Cartlidge
, et al.
·
Cell Death and Differentiation
·
69
PDF
BCL-XL inhibition by BH3-mimetic drugs induces apoptosis in models of Epstein-Barr virus-associated T/NK-cell lymphoma.
2020
·
Nenad Sejic
, Lindsay C George
, et al.
·
PubMed Central
·
26
Characterizing and Targeting of BCL ‐2 Family Members in Nasopharyngeal Carcinoma
2024
·
A. A. Thai
, R. J. Young
, et al.
·
Head & Neck
·
3
Insights into mechanisms of resistance to apoptosis in Epstein-Barr virus-associated T and NK cell lymphomas
2018
·
Nenad Sejic
·
University of Birmingham Institutional Research Archive (University of Birmingham)
Epstein-Barr virus and cellular DNA damage response
2014
·
Nenad Sejic
·
University of Birmingham Institutional Research Archive (University of Birmingham)
PDF
Show more works
View as search
Works count:
6
Citation count:
301
H-index:
3
I10-index:
3
Year
Topic
Type